SUMMARY
This work proposes that the combination of defective homing and reduced intrinsic regulatory T cell function synergize to reduce regulatory T-cell function sufficiently in the gut to counteract the protective effect of b7 deficiency on homing of conventional T cells, thus exacerbating intestinal inflammation.
BACKGROUND & AIMS:
Integrin a4b7 mediates lymphocyte trafficking to the gut and gut-associated lymphoid tissues, a process critical for recruitment of effector lymphocytes from the circulation to the gut mucosa in inflammatory bowel disease (IBD) and murine models of intestinal inflammation. Antibody blockade of b7 integrins generally is efficacious in IBD; however, some patients fail to respond, and a few patients can experience exacerbations. This study examined the effects of loss of b7 integrin function in murine models of IBD.
METHODS:
In a mouse IBD model caused by lack of interleukin 10, a cytokine important in CD25 hi FoxP3 þ regulatory T cell (Treg) function, genetic deletion of b7 integrin or antibody blockade of a4b7-mucosal addressin cell adhesion molecule-1 interaction paradoxically exacerbated colitis.
RESULTS: Loss of b7 impaired the capacity of Tregs homing to the gut and therefore suppress intestinal inflammation in an adoptive T-cell transfer model; however, the intrinsic suppressive function of b7-deficient Tregs remained intact, indicating that the b7 deficiency selectively impacts gut homing. Deletion of b7 integrin did not worsen colitis in an acute dextran sodium sulfate model in which Treg number and function were normal.
CONCLUSIONS:
In Integrin subunit beta (Itgb)7 -/-Il10 -/mice, loss of b7-dependent Treg homing to gut-associated lymphoid tissues combined with loss of intrinsic Treg function exacerbated intestinal inflammation. These results suggest that IBD patients with reduced CD25 hi FoxP3 þ Treg numbers or function or lack of interleukin 10 could be at risk for failure of a4b7 blocking therapy.
(Cell Mol Gastroenterol Hepatol 2020;9:369-385; https://doi.org/10.1016/j.jcmgh.2019. 10 .012) Keywords: Integrin b7 Blockade; Inflammatory Bowel Disease; Regulatory T Cells; Gut-Associated Lymphoid Tissue.
H omeostasis in the gut relies on a fine-tuned interplay of protective immunity against pathogens while maintaining tolerance to the commensal microbiota that comprises much of the intestinal microenvironment. Disruption of homeostasis can lead to intestinal disorders such as inflammatory bowel disease (IBD). [1] [2] [3] [4] A key feature of the inflammatory response in IBD is the rapid recruitment of leukocytes from the blood stream to the intestine via cell adhesion and transmigration through blood vessel walls, [5] [6] [7] leading to massive infiltration of mononuclear phagocytes, neutrophils, and inflammatory T cells into the intestinal lamina propria. [8] [9] [10] Leukocyte homing to the gut is regulated by a network of adhesion molecules and their ligands to ensure the proper location of immune cells for interaction with the local microenvironment. 11 This process is controlled largely by chemokines, which initiate a multistep adhesion cascade involving tethering, rolling, and cell arrest 12, 13 through modulation of integrin binding to endothelial and mucosal ligands (eg, aLb2/ intercellular adhesion molecule-1[ICAM-1], a4b1/vascular cell adhesion molecule-1[VCAM-1], and a4b7/mucosal addressin cell adhesion molecule-1 [MAdCAM-1]).
Blockade of mucosal T-cell homing is a therapeutic approach for IBD. 14 Integrin a4b7, which is expressed on the surface of gut-tropic effector lymphocytes, is an important cell adhesion molecule that mediates lymphocyte trafficking to gut and gut-associated lymphoid tissue (GALT). Vedolizumab, which specifically blocks integrin a4b7, is used for attenuating mucosal inflammation in patients with Crohn's disease (CD) and ulcerative colitis (UC). 15, 16 Despite the general effectiveness of vedolizumab, a significant number of IBD patients are nonresponders. The treatment was stopped or optimized because of a lack or loss of response in 36%-54% of IBD patients. 17, 18 Moreover, high doses of etrolizumab, which blocks b7 integrins (ie, a4b7, aEb7), is associated with a reduced clinical response. 19 Thus, although b7 blockade generally is beneficial in IBD, the reason that some patients are nonresponders remains unclear.
CD25 hi Foxp3 þ regulatory T cells (Tregs) can limit the development of colitis by reducing the accumulation and activity of effector cells in the inflamed mucosa. [20] [21] [22] [23] [24] Tregs can suppress immune responses by a wide variety of mechanisms, including secretion of immunosuppressive cytokines such as interleukin (IL)10. 25 IL10 is a major immunosuppressive product of Tregs to maintain homeostasis at the environmental interface of the intestine. 26 In addition, IL10deficient mice develop spontaneous IBD. 27, 28 Recent work has indicated that a4b7 is crucial for homing of Tregs to gut and GALT in patients with UC, 29 and b7 deficiency causes a reduction of murine Tregs in the gut. 30, 31 Here, we report that IL10-deficient mice, which are deficient in the Treg function of IL10 secretion, paradoxically developed exacerbated intestinal inflammation when b7 was genetically inactivated or a4b7-mediated gut homing was blocked by antibodies. These effects of loss of b7 function were associated with a loss of Tregs in the lamina propria owing to reduced Treg homing to the gut. By using an adoptive transfer model of intestinal inflammation, we show that b7-deficient Tregs are impaired in their capacity to populate the lamina propria and to prevent intestinal inflammation even though they show normal intrinsic suppressive functions. Taken together, these data suggest that the combination of reduced Tregs function in IL10 null mice and reduced Treg homing secondary to loss of b7 function, in combination, reduce Treg activity in the gut sufficiently to counteract the protective effect of blocking b7 homing of conventional T cells (Tconv). This conclusion implies that the presence of reduced Treg number or function or reduced IL10 expression could predispose to impaired efficacy of b7 blockade in IBD.
Results
b7 Deficiency Exacerbates Spontaneous Colitis in Il10 -/-Mice Integrin a4b7 mediates trafficking of Tconv to gut and GALT and antibody blockade of a4b7 benefits many patients with either CD or UC. 15, 16 To assess the role of b7 integrin in the development of chronic intestinal inflammation in a mouse model, we used an IL10-deficient mouse strain (B6.129P2-Il10tm1Cgn/J) that develops chronic colitis resembling IBD in human beings. 27, 28 IL10-deficient mice were crossed with b7-deficient mice, and the phenotypes of Integrin subunit beta (Itgb)7 -/-Il10 -/mice were compared with Itgb7 þ/þ Il10 -/mice.
As expected, 27, 28 Itgb7 þ/þ Il10 -/mice spontaneously developed diarrhea beginning at the age of 60-70 days under specific pathogen-free conditions in our animal facility. On average, the mice did not lose weight; however, 6 of 22 mice died by 70 days ( Figure 1B ), and 7 of 22 mice developed rectal prolapse. Unexpectedly, b7 deficiency exacerbated disease in Il10 -/mice as judged by dramatic weight loss accompanied by severe diarrhea and rectal bleeding ( Figure 1A and C). Furthermore, Itgb7 -/-Il10 -/mice almost uniformly developed rectal prolapse ( Figure 1D ) and more than two thirds of them died by approximately 70 days ( Figure 1B ). Itgb7 -/-Il10 -/mice were more anemic than integrin b7-replete Itgb7 þ/þ Il10 -/animals ( Figure 1E ). The exacerbated colitis in Itgb7 -/-Il10 -/mice was confirmed by significantly increased crypt distortion, mucosal ulceration, and infiltration of immune cells, compared with Itgb7 þ/þ Il10 -/mice ( Figure 1F and G). In addition, colonic expression of proinflammatory cytokines was increased significantly in Itgb7 -/-Il10 -/mice compared with Itgb7 þ/þ Il10 -/mice ( Figure 2 ).
To assess the contribution of b7 integrin further in mediating leukocyte recruitment and subsequent damage to the gut mucosa, we used piroxicam administration as a method to synchronize development of colitis in IL10deficient mice. 32 We administered piroxicam to IL10-null mice orally for 2 weeks. By 35 days after piroxicam initiation, approximately 80% of Itgb7 -/-Il10 -/mice died. In contrast, only approximately 28% of Itgb7 þ/þ Il10 -/mice died ( Figure 1H ). Thus, b7 deficiency exacerbated both spontaneous and induced IBD in IL10-deficient mice, a surprising result in light of the benefits of blockade of a4b7 in many IBD patients.
Integrin b7 Deficiency Results in Decreased Tregs in the Colon
Integrin a4b7 mediates lymphocyte trafficking to the intestinal mucosa by binding to its ligand, MAdCAM-1. To investigate whether the severe colitis in Itgb7 -/-Il10 -/mice was associated with reduced colonic Tregs, we enumerated Tregs and conventional CD4 þ T cells in the colonic lamina propria. Itgb7 -/-Il10 -/mice showed approximately 75% reduced Tregs in the colonic lamina propria compared with Itgb7 þ/þ Il10 -/mice ( Figure 3 ), consistent with observations in other models. [29] [30] [31] In contrast, a slight but statistically significant increase (P ¼ .02) in the number of colonic lamina propria CD4 þ T cells in Itgb7 þ/þ Il10 -/mice was observed, resulting in an approximately 80% reduction of Tregs as a percentage of colonic lamina propria CD4 þ T cells ( Figure 3A and B). The abundance of Tregs and total CD4 þ T cells in the spleen was not significantly different between Itgb7 -/-Il10 -/mice and Itgb7 þ/þ Il10 -/mice ( Figure 3A and B), indicating that Tregs generally were not reduced in the absence of b7. A similar reduction in colonic lamina propria Tregs was observed in piroxicamtreated Itgb7 -/-Il10 -/mice ( Figure 3C ). Importantly, expression of canonical Treg markers CD25 and Foxp3 was similar in Itgb7 -/-Il10 -/mice and Itgb7 þ/þ Il10 -/mice ( Figure 4 ). Furthermore, a wide variety of other Tregassociated proteins including OX40, CD152, T-bet, GATA3, and KLRG1 were expressed at similar levels in Tregs from spleen and lamina propria of Itgb7 -/-Il10 -/mice and Itgb7 þ/þ Il10 -/mice ( Figure 5 ). As expected, CD103 (aE), which requires pairing with b7, is not expressed in Itg-b7 -/-Il10 -/-Tregs ( Figure 5 ). In sum, these data show that integrin b7 deficiency results in a profound reduction of colonic Tregs in Itgb7 -/-Il10 -/mice. Moreover, the number of Tregs in mesenteric lymph nodes (MLNs) also was reduced significantly in Itgb7 -/-Il10 -/mice. However, the Treg numbers in peripheral lymph nodes (PLNs) was similar to Itgb7 þ/þ Il10 -/mice ( Figure 6 ). Thus, in this colitis model, the absence of b7 causes a profound reduction
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Incidence of Rectal prolapse (%) Itgb7 Il10 Itgb7 Il10 Figure 2 . RNA expression of cytokines in Itgb7 D/D Il10 -/mice and Itgb7 -/-Il10 -/mice. Messenger RNA (mRNA) expression of IL1b, tumor necrosis factor (TNF)-a, IL6, interferon (IFN)g, and IL17A in distal colon tissue from Itgb7 þ/þ Il10 -/mice (n ¼ 13) and Itgb7 -/-Il10 -/mice (n ¼ 12). Results are normalized to glyceraldehyde-3-phosphate dehydrogenase. Data represent means ± SEM. Two-tailed t test. *P < .01, **P < .01, ***P < .001
of Tregs in GALT; however, with the exception of aEb7, b7null Tregs that enter the colon express a typical repertoire of Treg-associated markers and transcription factors.
The foregoing results led us to ask whether the deleterious effects of loss of b7 function were mediated by effects on Tconv or Tregs. To investigate the role of b7 in Tconv cells and their capacity to induce colitis, we transferred CD4 þ CD25 -CD45RB high T cells (Tconv cells) from wild-type (WT) mice or Itgb7 -/mice into Rag1 -/recipient mice. Rag1 -/mice injected with WT Tconv cells showed a dramatic loss in body weight starting at 20-30 days, and one third of the mice died by 90 days ( Figure 7A and B). In contrast, Rag1 -/mice injected with Itgb7 -/-Tconv cells showed a significantly milder and delayed weight loss compared with WT Tconv cells and most of the mice survived ( Figure 7A and B) .
We next tested the role of integrin b7 on CD4 þ T-cell migration using the competitive homing assay. b7-deficient CD4 þ T cells were impaired for homing to MLNs and Peyer's patch (PP), but not PLNs and spleen (SP) ( Figure 7C ), which is consistent with previous studies. 33 Thus, b7deficient CD4 þ T cells manifest a defective migration to the colon, which reduces adoptive T-cell-transfer-induced colitis.
Integrin b7-Deficient Tregs Are Defective in the Capacity to Prevent Colitis
We examined the effect of b7 deficiency on the ability of Tregs to prevent intestinal inflammation in the adoptive Tcell transfer model. 34 Transfer of CD4 þ CD25 -CD45RB high T cells (CD4 þ Tconv) into Rag1 -/mice led to a severe colitis by 6-12 weeks after cell transfer. Loss of body weight started after 20 days ( Figure 8A ), and half of the mice had died by 90 days ( Figure 8B ). As expected, co-injection of Itgb7 þ/þ Tregs with Tconv prevented colitis ( Figure 8A and B), whereas injection of Itgb7 -/-Tregs with Tconv did not prevent disease. At 90 days, the disease markers in the mice receiving co-administered b7-deficient Tregs was similar to that of those receiving only Tconv ( Figure 8C and D) . Moreover, expression of proinflammatory cytokines in the colon was not significantly different in mice receiving Itgb7 -/-Tregs compared with Tconv alone, whereas those that had received Itgb7 þ/þ Tregs showed only minimal cytokine expression ( Figure 8E ). These results show that b7 deficiency impairs the capacity of Tregs to prevent adoptive T-cell-transfer-induced colitis, whereas it impairs the capacity of Tconv to cause colitis.
Defective Suppression of Colitis in b7-Deficient Tregs Is Ascribable to Defective Homing
To evaluate the possibility that integrin b7-deficient Tregs lacked suppressive capacity we examined their ability to inhibit T-cell proliferation. Green fluorescent protein positive (GFP þ ) Tregs were sorted from Itgb7 þ/þ Foxp3 GFP or Itgb7 -/-Foxp3 GFP mice and their capacity to suppress proliferation of CD4 þ CD25responder cells was compared in a dye dilution assay. Carboxyfluorescein succinimidyl ester (CFSE)-labeled responder cells stimulated with immobilized anti-CD3 and anti-CD28 in the presence of IL2 for 4 days at 37 C proliferated vigorously as indicated by the dilution of fluorescence ( Figure 9A ). The addition of a 1:1 ratio of b7-deficient or replete Tregs markedly reduced proliferation in these cultures ( Figure 9A ). The proliferation index as a function of Treg/responder ratio was not significantly different between cultures with Treg lacking b7 and those sufficient for b7 ( Figure 9B ). Furthermore, b7deficient Tregs showed similar expression of the antiinflammatory cytokines IL10 and transforming growth factor (TGF)-b1 as wild-type Tregs ( Figure 9C ). Thus, b7deficient Tregs are functionally intact with regard to their suppressive functions. The failure of Itgb7 -/-Tregs to efficiently suppress colitis despite normal intrinsic suppressive function suggested that defective homing of Itgb7 -/-Tregs may explain their reduced capacity to block colon inflammation. To test this idea, we used a competitive homing assay with GFP þ Tregs isolated from Itgb7 þ/þ Foxp3 GFP or Itgb7 -/-Foxp3 GFP mice, labeled them with a 1 mmol/L and 10 mmol/L concentration of eFluor670 proliferation dye, respectively, and co-injected equal numbers (1 Â 10 7 ) of differentially labeled cells into recipient mice. Lymphoid organs were harvested 3 hours after injection, and cells were isolated and analyzed by flow cytometry. Similar to the known effects of deficiency on Tconv homing ( Figure 7C ), b7-deficient Tregs homing to PP was reduced by approximately 90% compared with b7sufficient cells, whereas homing to MLN was reduced modestly (w50%). In contrast, homing of Tregs to PLN and SP were similar in Itgb7 -/and Itgb7 þ/þ Tregs ( Figure 9D ).
The absolute cell numbers of both WT or Itgb7 -/-Tregs in the different organs also were checked ( Figure 10 ). Thus, there is a profound reduction in Tregs in the GALT of Itgb7 -/mice that is attributable, at least in part, to defective homing of these cells, and this reduction can account for the exacerbation of colitis on an Il10 -/background.
b7 Deficiency Does Not Exacerbate Acute Dextran Sulfate Sodium-Induced Colitis Increased colitis in Itgb7 -/-Il10 -/mice seemed paradoxic in light of the therapeutic efficacy of a4b7 blockade in IBD patients. We reasoned that the combination of reduced functionality of Tregs lacking IL10 combined with a reduction of Tregs in the GALT of b7-deficient mice might synergistically reduce Treg function in the gut sufficient to exacerbate colitis. To test this idea, we examined the effect A B 10 10 10 Itgb7 Il10
KLRG1 T-bet GATA3 of b7 deficiency in a colitis model in which Treg function was normal. We administered dextran sulfate sodium (DSS) for 7 days and then analyzed the mice for an additional 7 days, times at which inflammation is dominated largely by the innate immune response to bacterial products that breach the intestinal barrier as a consequence of mucosal injury. 31, 35 Subsequently, an adaptive immune component can contribute to further chronic inflammation, 36 thus potentially accounting for the finding by Zhang et al that b7 deficiency exacerbated a later stage of DSS colitis. 28 Both Itgb7 þ/þ and Itgb7 -/mice showed similar rapid body weight loss during the initial phase of DSS treatment. Once DSS administration was halted, Itgb7 -/mice gained weight slightly but significantly more rapidly than Itgb7 þ/þ mice ( Figure 11A ). Itgb7 -/mice showed less mucosal immune cell infiltration and crypt destruction ( Figure 11B ), as shown by lower histologic scores ( Figure 11C ), and further supported by less anemia ( Figure 6D ). Thus, in sharp contrast to the IL10-deficient model, b7 deficiency did not exacerbate inflammation in this acute DSS model of colitis.
Antibody Blockade of a4b7-MAdCAM-1 Interaction Aggravates Spontaneous Colitis Induced by IL10 Deficiency
The foregoing studies showed that genetic inactivation of integrin b7 exacerbated colitis in Itgb7 -/-Il10 -/mice and ascribed the exacerbation to a combination of reduced Treg function and homing to GALT. These results raise 2 important issues: (1) b7 can combine with aE or a4; can loss of only a4b7 function exacerbate colitis in IL10-null mice? (2) Itgb7 -/mice lack b7 function throughout development: will loss of a4b7 function in an adult IL10-deficient mouse exacerbate colitis? MAdCAM-1, which is expressed preferentially on gut and GALT-associated endothelial cells, plays a vital role in a4b7-mediated leukocyte trafficking to the GALT and is a primary ligand of integrin a4b7. Because we did not have access to a function blocking antimurine a4b7, Il10 -/mice *** were treated with a MAdCAM-1 blocking antibody, MECA367, which inhibits binding of a4b7 integrin to MAdCAM-1 37 and ameliorates DSS-induced colitis. 38, 39 MECA367-treated Il10 -/mice showed profound weight loss and shorter survival compared with control IgG-treated Il10 -/mice ( Figure 12A  and B) . Furthermore, MECA367-treated Il10 -/mice showed more severe anemia ( Figure 12C ) and increased inflammation and colonic tissue injury ( Figure 12D and E) compared with control IgG-treated Il10 -/mice. Thus, blocking the interaction between MAdCAM-1 and integrin a4b7 in vivo aggravates spontaneous colitis induced by IL10 deficiency.
Discussion
Leukocyte homing to GALT has complex roles in the pathogenesis of IBD. 15, [40] [41] [42] Antibodies against b7 integrins, which inhibit leukocyte trafficking to the gut and GALT, are not uniformly efficacious at ameliorating IBD. 15 Here, we report that mice lacking IL10, a major immunosuppressive cytokine of Tregs, unexpectedly developed increased intestinal inflammation when b7 was genetically inactivated or a4b7-mediated GALT homing was blocked by antibodies. These effects of loss of b7 function were associated with reduced Tregs in the lamina propria owing to impaired Treg homing to the gut. In an adoptive transfer model of intestinal inflammation, we found that b7deficient Tregs are impaired in their capacity to colonize GALT and to oppose intestinal inflammation despite possessing normal intrinsic suppressive functions. We propose that the combination of reduced Treg function in IL10-null mice and reduced Treg homing owing to loss of b7 function, in combination, decrease net Treg suppressive activity in the gut sufficiently to counteract the protective effect of blocking b7 on homing of conventional T cells. Thus, Treg numbers or functions could affect the efficacy of b7 blockade in IBD (Figure 13 ). Surprisingly, loss of b7 function in mice lacking IL10 caused increased intestinal inflammation. Genetic b7 deficiency aggravated spontaneous colitis in IL10-deficient mice as judged by dramatic body weight loss accompanied by severe diarrhea and rectal bleeding. These symptoms were associated with histologic evidence of increased tissue damage and inflammation, worsened anemia, and increased colonic expression of proinflammatory cytokines. Importantly, because we were obliged to breed Il10 -/mice through crosses of Il10 þ/mice, it was not feasible to generate sufficient numbers of littermate Itgb7 -/-Il10 -/and Itgb7 þ/þ Il10 -/controls. Because b7 deficiency can impact the intestinal flora, 43 even though b7-null and WT mice were on a C57 BL/6 background and were cohoused, it is possible that some of the effects of b7 deficiency could be the result of an altered microbiome. That said, Il10 -/mice experienced a similar worsening of colitis after antibody blockade of a4b7-MAdCAM-1 interaction in comparison with cohoused IgG-treated littermates. Furthermore, in the adoptive transfer model of colitis, we documented that b7-null Tregs were defective in suppressing intestinal inflammation compared with WT Tregs when administered to cohoused littermate mice. These results sharply contrast with the beneficial effects of a4b7-blocking antibody in patients with active UC or CD. 15, 16 Earlier studies in mice also reported that inhibiting b7-integrin function attenuated acute and chronic murine models of intestinal inflammation. 44, 45 Thus, loss of b7 integrin function causes increased intestinal inflammation in IL10-deficient mice despite its often beneficial effects in other murine models and in human beings with IBD.
Vedolizumab blocks integrin a4b7 on both effector T cells and Tregs. Recent studies have reported that a4b7 is crucial for controlling homing of Tregs in patients with UC to the inflamed colon in vivo, 29 and b7 deficiency causes Treg depletion in the gut. 30, 31 Nevertheless, our data suggest that combined loss of Treg function and b7-dependent Treg homing to gut and GALT together can counteract a protective effect of b7 blockade of effector T-cell migration on intestinal inflammation. Integrin Itgb7 -/-Tregs were defective in their capacity to prevent induction of colitis in immune-deficient mice reconstituted with Tconv. We note that Denning et al reported that Itgb7 -/-Tregs could prevent colitis in their adoptive transfer model, a difference that might be a consequence of their use of a different immunodeficient recipient mouse strain. 30 Because Itgb7 -/-Tregs manifested intact suppressor function in vitro, this defect likely was owing to their reduced ability to populate the gut and GALT, a reduction we can ascribe to reduced migration to the GALT as shown in competitive homing experiments. Furthermore, vedolizumab can block the homing of Tregs from UC patients to the inflamed gut. 29 IL10 is a product of Tregs that is essential for the maintenance of intestinal homeostasis. It suppresses effector functions of T helper (Th)1/Th17 cells as well as natural killer cells and macrophages, thereby modulating both innate and adaptive immune responses 46 and muting pathogenic Th17 responses to pathobionts. 47 Tregs are a major source of IL10 to maintain homeostasis at the environmental interface of the intestine. 26 Thus, reduced homing of Itgb7 -/-Tregs to gut and GALT, combined with a lack of IL10, together will profoundly reduce Treg suppression of inflammation in the colon. In contrast, Itgb7 -/mice did not experience an exacerbation of the acute DSS model in which Treg function was not impaired. IBD can have a variety of underlying causes such as defects in the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome 48 or defective Tregs. We show that reduced integrin b7-mediated homing in the setting of reduced loss of IL10 exacerbates intestinal inflammation. Thus, loss of IL10 expression or reduced Treg numbers or functions in patients with IBD may impact their response to therapeutic inhibition of b7 integrins.
Materials and Methods

Antibodies and Reagents
The following antibodies were from BioLegend (San Diego, CA): CD4 (GK1.5), b7 (FIB504), Foxp3 (MF-14), anti-CD3 (2C11), anti-CD28 (37.51), IL10 (JES5-16E3), TGF-b1 (TW7-16B4), and anti-MAdCAM-1 (MECA367). Secondary AlexaFluor-labeled antibodies were from Jackson Immu-noResearch (West Grove, PA). The Foxp3 transcription factor fixation/permeabilization kit was purchased from eBioscience. CFSE and eFluor670 were purchased from Invitrogen (Carlsbad, CA) and BioLegend, respectively. Piroxicam was from MilliporeSigma (Burlington, MA). Ionomycin, brefeldin A, and monensin were from BioLegend. The MojoSort mouse CD3 T-cell isolation kit and mouse CD4 T-cell isolation kit were from BioLegend. Liberase TL (research grade) and DNAse I were from Roche (Basel, Switzerland). Recombinant mouse MAdCAM-1-Fc was purified by protein A beads as previously described. 49 
Mice
All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of California San Diego, and were conducted in accordance with federal regulations as well as institutional guidelines and regulations on animal studies. All mice were housed in specific pathogen-free conditions on corncob bedding and were fed ad libitum with a chow diet. C57BL/6 (CD45.1), C57BL/6 (CD45.2), Itgb7 -/-, Il10 -/-, Rag1 -/mice were from The Jackson Laboratory (Bar Harbor, ME). Foxp3 GFP mice have been described previously. 26, 50 All of the mice were on a C57BL/6 background. For experiments, 8-to 12-week-old mice were used. All injections of antibodies, control IgG, Tconv, and Tregs were performed during the light cycle.
Mononuclear cells were isolated from MLN, PP, PLN, SP, and colonic lamina propria as previously described. 13, 51 Cell counting with immunofluorescence cytometry was performed using an Accuri C6 Plus and FACSCalibur (BD Biosciences, San Diego, CA).
Mouse Colitis Models
Il10 -/mice spontaneously develop chronic IBD under specific pathogen-free conditions. The phenotypes of chronic colitis in Il10 -/mice (C57BL/6 genetic background) became more evident at 10-12 weeks. Because Il10 -/mice develop spontaneous colitis, which has negative consequences on their capacity to breed, we separately crossed the mice as Itgb7 þ/þ Il10 þ/-Â Itgb7 þ/þ Il10 þ/and Itgb7 -/-Il10 þ/-Â Itgb7 -/-Il10 þ/to generate Itgb7 þ/þ Il10 -/and Itgb7 -/-Il10 -/-, respectively. Sex-matched Itgb7 þ/þ Il10 -/and Itgb7 -/-Il10 -/mice were cohoused starting at 3-4 weeks after weaning. For piroxicam treatment, mice were administered piroxicam (200 ppm in their diet everyday) for 2 weeks and killed 3 weeks after the end of piroxicam treatment. 32 For the adoptive T-cell-transfer model, 8-to 10week-old mice were used. CD4 þ CD25 -CD45RB high conventional T cells (5 Â 10 5 ) from C57BL/6 mice were injected intraperitoneally into cohoused Rag1 -/mice in the presence or absence of 1 Â 10 5 CD4 þ CD25 þ CD45RB low Tregs derived from the indicated mutant genotype littermate mice (0.2 mL phosphate-buffered saline each recipient). In acute colitis experiments, cohoused Itgb7 þ/þ or Itgb7 -/littermates were administered 1.5% (wt/vol) DSS with a molecular mass of 36-50 kilodaltons (MP Biomedicals, Irvine, CA) in drinking water for a total of 7 days (days 0-7), followed by plain drinking water (days [8] [9] [10] [11] [12] [13] [14] . Mice were assessed daily for body weight, diarrhea, and bloody stool. The disease activity index and histologic damage were assessed by trained individuals blinded to the treatment groups, as reported previously. 31 For anti--MAdCAM-1 blocking antibody MECA367 treatment, the Il10 -/cohoused littermates were injected intraperitoneally with MECA367 or control IgG (100 mg/mouse) every 4 days. Mice were euthanized, and peripheral blood was collected to test hemoglobin levels. Colons were isolated for histology and quantitative polymerase chain reaction (PCR) analysis.
Mouse body weight was measured every day and values are shown as a percentage of the original weight. During the duration of the experiment, we assessed the clinical progression of colitis by daily scoring a disease activity index. The disease activity index is the combined score of body weight loss, stool consistency, and rectal bleeding and prolapse, as follows: (1) weight loss: 0 (no loss), 1 (1%-5%), 2 (5%-10%), 3 (10%-20%), and 4 (>20%); (2) stool consistency: 0 (normal),1 (soft), 2 (very soft), and 3 (diarrhea); (3) rectal bleeding: 0 (none), 1 (red), 2 (dark red), and 3 (gross bleeding); and (4) rectal prolapse: 0 (none), 1 (signs of prolapse), 2 (clear prolapse), and 3 (extensive prolapse). Mice were killed at week 15.
Histology
Formalin-fixed, paraffin-embedded, Swiss-rolled colon sections of 4-mm thickness were mounted on glass slides and followed by H&E staining or periodic acid-Schiff staining. Images were acquired with a Nanozoomer Slide Scanner (Hamamatsu Nanozoomer 2.0 HT Slide Scanner, Hamamatsu City, Japan). Blinded histologic scoring was performed by 2 investigators based on the method described previously. 52 Two different scoring schemes were used (Tables 1 and 2 ).
Flow Cytometry
Cells isolated from mouse tissues were washed and resuspended in Hank's balanced salt solution containing 0.1% bovine serum albumin and 1 mmol/L Ca 2þ /Mg 2þ and stained with conjugated antibody for 30 minutes at 4 C. Then cells were washed twice before flow cytometry analysis using an Accuri C6 Plus or FACSCalibur (BD Biosciences). Data were analyzed using FlowJo software (FlowJo, Ashland, OR). For intracellular detection of cytokines, splenocytes were stimulated ex vivo with Phorbol 12myristate 13-acetate and ionomycin in the presence of brefeldin A and monensin for 6 hours at 37 C; cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) and permeabilized with the Foxp3 transcription factor fixation/permeabilization kit (eBioscience) before IL10, TGF-b1, and Foxp3 staining.
Treg Suppression Assays
CD4 þ CD25 -T cells (responder cells) were isolated from spleens of C57BL/6 (CD45.1) WT mice by magnetic separation using the CD4 þ T-cell negative isolation kit (BioLegend); a biotin-conjugated anti-CD25 (PC61; BioLegend) antibody was included to deplete Tregs. GFP þ Tregs were sorted with a FACSAria 2 (BD Biosciences) from Itgb7 þ/þ Foxp3 GFP or Itgb7 -/-Foxp3 GFP mice. Responder cells were labeled with CFSE and cocultured with Tregs (8:1, 4:1, 2:1, and 1:1 ratios) in the presence of 5 mg/mL immobilized anti-CD3 (2C11) and anti-CD28 (37.51) and IL2 for 4 days at 37 C. The proliferation index was calculated by FlowJo v10.
In Vivo Competitive Lymphocyte Homing
The competitive homing assay used high-and low-dose cell tracker, as described. 53 GFP þ Tregs were sorted with a FACSAria 2 (BD Biosciences) from Itgb7 þ/þ Foxp3 GFP or Itgb7 -/-Foxp3 GFP mice and labeled with 1 mmol/L and 10 mmol/L of eFluor670, resulting in readily discriminated cell populations ( Figure 14 ). Equal numbers of differentially labeled Tregs (1 Â 10 7 ) were mixed and then injected intravenously into C57BL/6 recipient mice. Lymphoid organs were harvested 3 hours after injection and isolated cells were analyzed by flow cytometry. The ratio of Itgb7 -/-Tregs (10 mmol/L eFluor670) to Itgb7 þ/þ Tregs (1 mmol/L eFluor670) from different lymphoid organs are shown. For a competitive homing assay of b7-deficient CD4 þ T cells, CD4 þ T cells were isolated by the MojoSort mouse CD4 Tcell isolation kit from Itgb7 þ/þ or Itgb7 -/mice and labeled with 1 mmol/L of CFSE and eFluor670, respectively. Hyperproliferation, irregular crypts, goblet cell loss 2
Mild to moderate crypt loss (10%-50%) 3 Severe crypt loss (50%-90%) 4 Complete crypt loss, surface epithelium intact 5
Small-to medium-sized ulcer (<10 crypt widths) 6 Large ulcer (>10 crypt widths)
Infiltration with inflammatory cells (0-6) 
Real-Time Quantitative PCR Analyses
Total RNA was isolated from colon using a tissue homogenizer (JXFSTPRP-24; ThunderSci, Shanghai, China) and TRIzol reagent according to the manufacturer's protocol (Thermo Fisher Scientific, Waltham, MA). For gene expression analysis, single-stranded complementary DNA was produced from 10 mg colonic total RNA using Super-Script III First-Strand synthesis and oligo-dT (deoxythymine) primers according to the manufacturer's protocol (Thermo Fisher Scientific). The kappa SybrFast quantitative PCR kit (Kapa Biosystems, Wilmington, MA) and thermal cycler (CFX96 Real-Time System; Bio-Rad Laboratories, Berkeley, CA) were used to determine the relative levels of the genes analyzed (primer sequences are shown in Table 3 ) according to the manufacturer's protocol. The 2-delta delta CT ( -DDCT ) method was used for analysis, and data were normalized to glyceraldehyde-3phosphate dehydrogenase. Control values (WT mice or Rag1 -/mice injected with phosphate-buffered saline) were set to 1 for comparisons.
Statistical Analysis
Statistical analysis was performed using PRISM software (version 6.00, GraphPad Software, San Diego, CA), and all data sets were checked for Gaussian normality distribution. Data analysis was performed using a 2-tailed t test, 1-way or 2-way analysis of variance, followed by the Bonferroni 
WT-1PM
Itgb7 -10PM -/-
WT-10PM
Itgb7 -1PM -/-eFluor670 eFluor670 A B Figure 14 . Validation of dual-label intensity homing assay. (A) GFP þ Tregs were sorted with a FACSAria 2 (BD Biosciences) from Itgb7 þ/þ Foxp3 GFP or Itgb7 -/-Foxp3 GFP mice and labeled with 1 or 10 mmol/L of eFluor670, respectively. Equal numbers (1 X 10 7 ) of differentially labeled Tregs were mixed and then injected intravenously into C57BL/6 recipient mice. Spleens were harvested 3 hours after injection and isolated cells were analyzed by flow cytometry. The representative histograms were gated on GFP þ Tregs. As shown in this histogram, this differential labeling produces 2 readily distinguished cell populations. (B) The same experiment was performed as in panel A, with the cell types receiving each concentration of eFluor670 reversed, that is, Itgb7 þ/þ Foxp3 GFP (WT) or Itgb7 -/-Foxp3 GFP (Itgb7 -/-) mice were labeled with 10 mmol/L or 1 mmol/L of eFluor670, respectively.
posttest as indicated in the figure legends. The resulting P values are indicated as follows: *, .01< P < .05; **, .001< P < .01; ***, P < .001. Plotted data are the means ± SEM of at least 3 independent experiments.
